Key result
Vericiguat improves cardiac function in diabetic cardiomyopathy mice by targeting QRICH1 to suppress pyroptosis.
Why the study?
Diabetic cardiomyopathy involves myocardial metabolic remodeling and inflammatory cell death, yet the transcriptional regulators linking metabolic stress to cardiomyocyte injury remain poorly defined.
Does QRICH1 promote PDK4-dependent mitochondrial dysfunction and pyroptosis in diabetic cardiomyopathy, and can vericiguat improve cardiac function by targeting QRICH1?
Does QRICH1 promote PDK4-dependent mitochondrial dysfunction and pyroptosis in diabetic cardiomyopathy, and can vericiguat improve cardiac function by targeting QRICH1?
QRICH1 drives mitochondrial dysfunction and pyroptosis in diabetic cardiomyopathy via PDK4 activation, and vericiguat targets QRICH1 to improve cardiac function in a preclinical mouse model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for vericiguat in diabetic cardiomyopathy; prospective trials required before clinical consideration.
BACKGROUND: Diabetic cardiomyopathy (DCM) is characterized by myocardial metabolic remodeling and inflammatory cell death, yet the transcriptional regulators linking metabolic stress to cardiomyocyte injury remain poorly defined. METHODS: Glutamine-rich protein 1 (QRICH1) expression was examined in hearts of mice with high-fat diet and streptozotocin-induced type 2 diabetes and in cardiomyocytes exposed to high glucose plus palmitic acid. QRICH1 transcriptional regulation of pyruvate dehydrogenase kinase 4 (PDK4) was verified by chromatin immunoprecipitation and dual-luciferase assays, and the effects of QRICH1 overexpression and PDK4 knockdown were assessed in vitro. Drug repurposing was performed by molecular docking and a drug affinity responsive target stability assay. RESULTS: QRICH1 was markedly upregulated in diabetic myocardium and under glucolipotoxic conditions. QRICH1 directly bound the PDK4 promoter and transactivated its expression. QRICH1 overexpression induced caspase-1-dependent pyroptosis, impaired mitochondrial respiration, and promoted cytosolic mitochondrial DNA (mtDNA) leakage with inflammatory signaling activation, and these changes were partially reversed by PDK4 knockdown. Vericiguat showed the strongest binding affinity for QRICH1 among screened cardiovascular drugs. In DCM mice, vericiguat significantly improved cardiac function, downregulated PDK4, and restored myocardial AKT phosphorylation. CONCLUSIONS: QRICH1 sustains PDK4 expression under glucolipotoxic stress, driving mitochondrial dysfunction, mtDNA release, and pyroptosis, and vericiguat represents a repurposing candidate for myocardial protection in DCM.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied Diabetic cardiomyopathy. Vericiguat (in vivo) / QRICH1 overexpression and PDK4 knockdown (in vitro) was evaluated on Cardiac function, PDK4 expression, mitochondrial respiration, and caspase-1-dependent pyroptosis. QRICH1 transactivated PDK4 to drive mitochondrial dysfunction and caspase-1-dependent pyroptosis in diabetic cardiomyopathy, while vericiguat bound QRICH1, downregulated PDK4, and improved cardiac function in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: